Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
- Written by PR Newswire
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research
FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™...














